Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group - Gilde Healthcare

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

September 3, 2025
Utrecht (the Netherlands)

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September 1, 2025. Dr. Stark has more than 20 years of experience in the international medical device industry and brings along extensive operational and strategic leadership expertise.

In his new role, Dr. Stark will manage the existing companies, Koscher & Würtz and Christian Diener, as well as future acquisitions within the group. The aim is to further expand the group’s position as a leading supplier of instruments for neurosurgery, minimally invasive surgery, robotics, and orthopedics.

“With Dr. Christian Stark, we are gaining an internationally recognized leader who brings both deep industry knowledge and a proven track record of success in the international medtech business. He will play a key role in driving our growth strategy and building a strong, internationally competitive group,” explains Rafael Natanek, General Partner at Gilde Healthcare Private Equity.

Dr. Stark emphasizes: “The group combines decades of experience in the development and manufacture of customized surgical instruments with a market-leading reputation. By combining expertise, state-of-the-art manufacturing technology, and international reach, we can offer our customers not only the highest quality, but also a constantly growing, innovative product portfolio.”

Before joining the group, Dr. Stark held senior positions in the international healthcare and medical technology sector at various corporations and institutions, gaining over two decades of experience in different leadership roles and regions. His doctorate in engineering focused on the digitization of production processes, giving him extensive expertise in combining technology, efficiency improvements, and innovation.

The group employs a total of around 300 highly skilled workers across several production sites in the Tuttlingen area. As part of a strong medical technology group, the individual companies benefit from:
·     An expanded product and service portfolio through the pooling of specialist expertise
·     Synergy effects in procurement, manufacturing, and quality management
·     Joint innovative strength through shared development resources and know-how transfer
·     Strong international market access through international customer network and joint sales activities

This structure not only opens up growth opportunities for existing members, but also offers attractive potential for other companies looking to strengthen their competitive position in the global medtech market.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medical technologies (MedTech) and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025